Definium Therapeutics, Inc.
About Definium Therapeutics, Inc.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$183.8M
- Total assets
- $440.1M
- Market cap
- $2.6B
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.6B
- Shares outstanding
- 111.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 3, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $183.8M.
- Trading 6% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Definium Therapeutics, Inc..
Write a review
News about Definium Therapeutics, Inc.
News & sentiment via Polygon.io
